Intas Pharmaceuticals, one of the world’s leading pharmaceutical companies, has made a progressive breakthrough in the Antifungal Therapy domain with the launch of the world’s first Super Bioavailable Itraconazole-SB 100mg by the Brand Name of Itaspor-SB Forte/Subawin. The cost of the therapy is also reduced substantially. Recently, it has been approved by Indian Regulatory Authorities.
Dr Alok Chaturvedi, Senior Vice-President & Head – Medical Affairs, Intas Pharmaceuticals, said, “Intas’ newest formulation within the 25 year old brand Itaspor is formulated with Super Bioavailable (SB) Technology that makes 1 Itaspor-SB Forte capsule equivalent to conventional 200mg Itraconazole.”
Usual Itraconazole mainstay drug to fight fungal infection has high result variance and low patient compliance because of dosing dependence upon food, acidic beverage, antacids consumption etc. and overall cost of treatment. Itaspor SB Forte/Subawin is expected to improve patient compliance and reduce the Doctor’s counselling time. It will reduce dosing to half.
